TABLE 2.

Fasting and postprandial glucose and hormone concentrations during the baseline meal study and after 6 and 12 wk of caloric restriction for patients with type 2 diabetes¹

Concentrations	Baseline study	6 wk study	12 wk study	P2	Post hoc comparisons
Fasting glucose, mmol/L	9.8 ± 1.3	5.9 ± 0.2	6.2 ± 0.3	<1 × 10−4	BL > (6 wk = 12 wk)
Peak postprandial glucose, mmol/L	14.9 ± 1.4	11.0 ± 0.4	10.9 ± 0.5	<1 × 10−4	BL > (6 wk = 12 wk)
AAB glucose, mmol/L × 6 h	197 ± 101	186 ± 68	160 ± 38	0.28	NA
Fasting insulin, pmol/L	89 ± 13	51 ± 11	51 ± 11	<1 × 10−4	BL > (6wk = 12 wk)
Peak postprandial insulin, pmol/L	369 ± 120	325 ± 66	310 ± 74	0.97	NA
AAB insulin, nmol/L × 6 h	29.5 ± 8.9	29.5 ± 6.2	23.8 ± 5.4	0.69	NA
Fasting C-peptide, nmol/L	1.8 ± 0.2	1.3 ± 0.2	1.2 ± 0.2	<1 × 10−4	BL > (6 wk = 12 wk)
Peak postprandial C-peptide, nmol/L	3.5 ± 0.5	3.7 ± 0.5	3.5 ± 0.3	0.40	NA
AAB C-peptide, nmol/L × 6 h	296 ± 20	402 ± 48	339 ± 32	0.19	NA
Fasting glucagon, ng/L	91 ± 12	71 ± 10	71 ± 9	0.02	BL > (6 wk = 12 wk)
Peak postprandial glucagon, ng/L	107 ± 12	95 ± 9	96 ± 10	0.19	NA
AAB glucagon, μg/L × 6 h	0.7 ± 1.0	2.9 ± 0.9	3.8 ± 0.6	0.006	BL < (6 wk = 12 wk)

¹Values are means ± SEMs, n = 9 except at 12 wk, n = 8. AAB, area above basal; BL, baseline; NA, not applicable.

²Determined by repeated-measures ANOVA.